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Abstract
Background: Recent research has implicated that mutations in the neurexin-1 (NRXN1) gene on chromosome
2p16.3 might play a role in schizophrenia, autism, and nicotine dependence. In order to explore the association of
NRXN1 polymorphisms with schizophrenia, we made a case-control association study in Chinese Han population.
Methods: We examined six tag single nucleotide polymorphisms (SNPs) spanning 116.7 kb of NRXN1 in 768
schizophrenic patients and 738 healthy control subjects. The association of NRXN1 polymorphisms with
schizophrenia and the age-at-onset of this disease were explored.
Results: Our results showed that four SNPs of NRXN1 gene were significantly associated with schizophrenia
(rs10490168: G > A, p = 0.017; rs2024513: A > G, p = 0.006; rs13382584: T > C, p = 0.009; and rs1558852: G > A, p =
0.031). Furthermore, the association of SNP rs2024513 with schizophrenia remained significance after the Bonferroni
correction. Haplotypes consisting of above six SNPs also showed significantly associated with schizophrenia (global
chi-square = 14.725, p = 0.022). A protective haplotype AGTGCA remained associated with schizophrenia, even
after 10,000 permutation tests (empirical p-value = 0.043). However, we did not find any association with age-at-
onset of schizophrenia with NRXN1 polymorphisms.
Conclusions: Our findings suggest that NRXN1 might represent a major susceptibility gene for schizophrenia in
Chinese Han population.
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Background
Schizophrenia is a common psychiatric disorder charac-
terized by profound disturbances of thinking, emotion,
and social functioning. It affects approximately 1% of
the worldwide population and accounts for about 2.5%
of healthcare costs [1]. Aberrant synaptic connectivity is
a prominent feature of schizophrenia’s neuropathology
[2]. Recently, several groups have identified schizophre-
nic patients who showed microdeletions disrupting the
promoter and N-terminal encoding exons of neurexin 1
(NRXN1) alpha [3-5]. Kirov et al. have found a deletion
disrupting the NRXN1 gene at 2p16.3 in a mother and
two affected siblings from one family, and identical
twins concordant for child-onset schizophrenia, respec-
tively [3-5]. Furthermore, copy number variations
(CNVs) in NRXN1 gene have also previously been
implicated in autism, mental retardation and nicotine
dependence [6-11].
Neurexins, including NRXN1, NRXN2, NRXN3, are
cell-surface receptors that bind neuroligins (NLGNs)
and form a Ca
2+-dependent neurexin/neuroligin com-
plex at synapses in the central nervous system [12,13].
The NRXN - NLGN complex plays an important role
during the GABAergic and glutamatergic neurotrans-
mission [12]. There is prevailing evidence implicating
both neurexins and neuroligins as primary factors in
neuropsychiatric disorders [3-11].
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didate gene for schizophrenia [3-6]. Resequencing has
been applied to identify the rare mutations of this gene,
but the linkage and association studies of NRXN1 poly-
morphisms in Chinese Han population remained still
insufficient. In this study, we attempted to investigate
the association between the NRXN1 gene polymorph-
isms and schizophrenia and age-at-onset of this disease
in 768 patients with schizophrenia and 738 healthy con-
trol subjects of Chinese Han population.
Methods
Our study sample consisted of 768 patients with schizo-
phrenia (360 men and 408 women; mean age: 33.5 ± 8.7
years) and 738 healthy controls (358 men and 380
women; mean age: 32.2 ± 6.4 years). All of the partici-
pants were Chinese Han descendants. The patients were
recruited from the Institute of Mental Health, Peking
University, China. The consensus diagnoses were made
by at least two experienced psychiatrists according to
the Diagnosis and statistic manual of mental disorders,
4
th edition (DSM-IV) criteria for schizophrenia. The age
of clinical symptoms onset (12~53 years, mean 23.8 ±
7.8 years) was retrospectively estimated as the time of
emergence of any schizophrenic symptoms according to
the DSM-IV. None had severe medical complications.
Healthy controls were recruited from communities with
simple non-structured interview performed by psychia-
trists, who excluded individuals with history of mental
health and neurological diseases. The control subjects
l i v ei nt h es a m ea r e aw i t hp a t i e n t s ,a n dw e r eg r o u p -
matched to patients by gender, age, and ethnicity. The
objectives and procedures of the study were explained
to all participants and written informed consent was
obtained. Research ethics committee approval was
obtained from the Ethical Committee of Institute of
Mental Health, Peking University.
Peripheral blood samples were collected from all sub-
jects. Genomic DNA was extracted using the Qiagen
QIAamp DNA Mini Kit. Considering Kirov et al.’s
report that micordeletions spanning the promoter and
the first exon of the NRXN1 gene might increase the
risk of developing schizophrenia, we selected six tag sin-
gle nucleotide polymorphisms (tagSNPs) locating the
promoter and the first exon of this gene, according to
the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP)
[3-5]. All of the six tagSNPs were genotyped with the
TaqMan genotyping methods according to the manufac-
turer’s protocol, where allelic discrimination and analysis
were performed using an ABI Prism 7300 Sequence
Detection System (Applied Biosystems, CA). The infor-
mation of ABI Taqman assays and context sequences of
six SNPs are given in Table 1. The standard TaqMan
®
SNP genotyping assay protocol was performed for
polymerase chain reactions (PCRs), which contained
10 ng of DNA, 5 μL of 2 ×TaqMan Universal PCR Mas-
ter Mix (Applied Biosystems, Foster City, CA), 0.5 μLo f
20 × SNP Genotyping Assay Mix (Applied Biosystems,
Foster City, CA), and 4.5 μL of water, for a total volume
of 10 μL. The conditions of PCR amplification were as
follows: 1 enzyme activation step at 95.0°C for 10 min,
and 40 alternating cycles of denaturation at 92.0° C for
15 s and re-annealing and extension at 60.0°C for 60 s.
To evaluate the quality of genotyping, 5% of the samples
were randomly selected and re-genotyped, and the geno-
typing consistency rate was more than 98%.
The statistic power of our sample size was calculated by
the genetic power calculator (GPC, http://pngu.mgh.har-
vard.edu/~purcell/gpc/cc2.html) [14]. Deviation of the
genotype counts from the Hardy-Weinberg equilibrium
was tested using a chi-square goodness-of-fit test. The
pairwise linkage disequilibrium (LD) analysis was applied
to detect the inter-marker relationship, using D’-values.
The case-control association analysis was performed by
the Haploview version 4.1 (http://www.broad.mit.edu/
mpg/haploview/), a powerful software platform for com-
puting single locus and multi-marker haplotype associa-
tion tests [15]. Bonferroni corrections for multiple tests
were carried out to exclude type I errors. For the haplo-
type analyses, 10,000 times of permutation tests were per-
formed to control false positive results. The LD plot of 6
SNPs at the 5’UTR of NRXN1 gene and its regional plots
across this gene were constructed by using the Haploview
v4.1 software in 738 healthy control subjects. To indicate
the relative position of above 6 SNPs and the other SNPs
across the NRXN1 gene download from the HapMap stage
II dataset, we then further constructed the regional LD
plots using the LocusZoom (http://csg.sph.umich.edu/
locuszoom/) [16]. Associations between age-at-onset and
different genotype carriers were determined by one-way
ANOVA tests with the SPSS 13.0. Considering that the
mean age of control group was younger than that of case
group, we implemented the logistic regression analysis,
with diagnosis as dependent variable, and 6 tagSNPs and
age at enrolled of subjects as independent variables.
Results were considered significant at two-tailed P < 0.05.
Results
Six SNPs in the NRXN1 gene were genotyped in 768 schi-
zophrenia patients and 738 healthy control subjects of
Chinese Han population. The size of our sample was suffi-
cient to detect a significant difference with a power of
more than 90% assuming an odds ratio (OR) values of AA
as 1.7 with a minor allele frequency of 0.1. The genotype
distributions of the six SNPs for patients and controls
were in Hardy-Weinberg equilibrium (Table 2). Allele and
genotype frequencies of the six SNPs between patients
and controls are shown in Table 2. Significant differences
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trols at four SNPs, rs10490168 (G > A, p = 0.017),
rs2024513 (A > G, p = 0.006), rs13382584 (T > C, p =
0.009), and rs1558852 (G > A, p = 0.031). However, only
the difference in the allele frequencies of rs2024513
remained significance after the Bonferroni correction. For
control the confounding effects of age of subjects, we used
the logistic regression to identify whether the age influence
the marker-diagnosis effects. However, the age of subjects
when they were enrolled in the current study did
not showed any significant confounding effects on maker-
diagnosis association (p =0 . 0 5 8 ) .
To further analyze the haplotype structure in our sam-
ple, we computed pairwise LD for all possible combina-
tions of the six SNPs using D’ and r
2 values. Figure 1
showed the LD plot of constructed by the six SNPs
locating at the 5’UTR of NRXN1 and regional LD plots
across the NRXN1 gene. Haplotypes consisting of above
six SNPs also showed significantly associated with schi-
zophrenia (global chi-square = 14.725, p =0 . 0 2 2 ) .A
protective haplotype AGTGCA remained associated
with schizophrenia, even after 10,000 permutation tests
(empirical p-value = 0.043).
To explore the potential association of age-at-onset of
schizophrenia with NRXN1 polymorphisms, we carried
out association analysis tests using the six SNPs at
NRXN1 gene. However, the results of one-way ANOVA
tests revealed there was no association of age-at-onset
of schizophrenia with six SNPs at NRXN1 gene (p >
0.05) (data not shown). Furthermore, we also did not
find the association between NRXN1 polymorphisms
and early-onset schizophrenia.
Discussion
Neurexins, including NRXN1 and other members of the
neurexin family, are synaptic neuronal adhesion
Table 1 Information of TaqMan assays and context sequences of 6 SNPs examinaed
ID SNPs Position Location Context Sequence ([VIC/FAM])
1 rs10490168 50988978 intron TGAATTGATAAAACAGTAACACTGA[C/T]AAAAATACATACACACATTCACACAC
2 rs2024513 51005523 intron GAAGTGTTCTTTCTTAGATACATGA[A/G]GTCTTGGTAACCTTAATGGCTATTT
3 rs10174398 51049105 intron ACCAGTCCACCTCTATCTGTACCCA[C/T]GCTCTCTCCATATAATGTTCTTCTC
4 rs10195460 51082210 intron CTAAAGGGAGATCAATTAAGCATAC[A/G]TTTTTCCACCTTTTAAAATAATACT
5 rs13382584 51100798 intron TCTTTACAAATGTAACCACCACCCA[C/T]ATCATGCCCAATGCTCCATTGTTTT
6 rs1558852 51105641 intron TTAATACATGATCTGTATTGGGAGA[A/G]TCATCCATTCTCAATTAATTATTCA
Table 2 Comparison of genotype and allele frequencies of six SNPs at the NRXN1 gene between schizophrenic
patients and healthy control subjects
Makers Genotype N (Freq.) Chi-square
(df = 2)
p- value HWEP Allele N (Freq.) Chi-square
(df = 1)
p- value OR (95% CI)
rs10490168 AA AG GG A G
Cases 10(0.013) 173(0.225) 585(0.762) 6.049 0.048 0.485 193(0.126) 1343(0.874) 5.677 0.017 0.78(0.63-0.96)
Controls 13(0.018) 204(0.276) 521(0.706) 0.168 230(0.156) 1246(0.844)
rs2024513 AA AG GG A G
Cases 544(0.708) 206(0.268) 18(0.023) 7.521 0.023 0.772 1294
(0.842)
242(0.158) 7.327 0.006 1.30(1.07-1.56)
Controls 480(0.650) 228(0.309) 30(0.041) 0.655 1188
(0.805)
288(0.195)
rs10174398 CC CT TT C T
Cases 276(0.359) 359(0.467) 133(0.173) 0.727 0.695 0.382 911(0.593) 625(0.407) 1.064 0.397 1.06(0.92-1.23)
Controls 254(0.344) 345(0.467) 139(0.188) 0.256 853(0.578) 623(0.422)
rs10195460 AA AG GG A G
Cases 61(0.079) 318(0.414) 389(0.507) 1.197 0.549 0.721 440(0.286) 1096(0.714) 0.972 0.323 0.92(0.79-1.08)
Controls 62(0.084) 323(0.438) 353(0.478) 0.321 447(0.303) 1029(0.697)
rs13382584 CC CT TT C T
Cases 14(0.018) 200(0.260) 554(0.721) 7.075 0.029 0.404 228(0.148) 1308(0.852) 6.821 0.009 0.77(0.64-0.94)
Controls 23(0.031) 225(0.305) 489(0.664) 0.638 271(0.184) 1203(0.816)
rs1558852 AA AG GG A G
Cases 234(0.305) 383(0.499) 151(0.197) 4.666 0.097 0.799 851(0.554) 685(0.446) 4.627 0.031 0.85(0.74-0.99)
Controls 259(0.351) 357(0.484) 122(0.165) 0.956 875(0.593) 601(0.407)
Freq., frequency; HWEP: the p-value for Hardy-Weinberg equilibrium tests; OR, odds ratio; CI, confidence interval.
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form a Ca
2+ - dependent NRXN - NLGN synpatic com-
plex in the central nervous system. This NRXN - NLGN
complex is required for neurotransmission at synapses
and is involved in the presynaptic and postsynaptic dif-
ferentiation of GABAergic and glutamatergic synapse
[12,17-20]. The de novo alterations of the NRXN1 gene
and their roles in the pathogenesis of autism and schizo-
phrenia have been reported by some studies [4,21,22].
Based on these findings, we hypothesized that the
NRXN1 might be a strong candidate gene for schizo-
phrenia. However, there has been no further evidence of
association between NRXN1 polymorphisms and schizo-
phrenia in Chinese Han population. In the present
study, we investigated the association of NRXN1 poly-
morphisms and schizophrenia in 768 cases and 738
healthy control subjects of Chinese Han population. We
detected six tagSNPs of NRXN1 gene in our samples.
Significant differences were found in allele frequencies
between patients and controls at four SNPs
(rs10490168, rs2024513, rs13382584, rs1558852). How-
ever, only the difference in the allele frequencies of
rs2024513 remained significance after the stringent Bon-
ferroni multiple-test correction. Further association ana-
lysis of haplotypes consist of six SNPs at the NRXN1
gene with schizophrenia were performed. Three haplo-
types at the NRXN1 gene were found to be associated
with schizophrenia. The protective haplotype AGTGCA
consist of above 6 SNPs remained significantly asso-
ciated with schizophrenia, even after Bonferroni correc-
tion (Table 3).
By microarray analysis in 2,977 European patients with
schizophrenia and 33,746 European controls, Rujescu
et al. identified 66 deletions and 5 duplications in the
NRXN1 gene: 12 deletions and 2 duplications occurred
in schizophrenic patients (0.47%), compared to 49 and 3
in controls (0.15%) [5]. There was no common break-
point, and the CNVs varied from 18 to 420 kb. No
CNVs were found in the NRXN2 or NRXN3 genes. By
restricting the association analysis to CNVs that dis-
rupted exons, they identified a significant association
with a high odds ratio (0.24% cases vs.0 . 0 1 5 %c o n t r o l s ,
p = 0.0027, OR = 8.97). Rujescu et al suggested that
NRXN1 deletions affecting exons may confer risk of
schizophrenia [5]. Several previous studies have sug-
gested that the NRXN1 gene might be the susceptibility
gene of schizophrenia and other neurodevelopmental
disorders.
Kirov et al.’s reports CNVs in NRXN1 gene implicated
with schizophrenia and other mental disorders mostly
are the rare polymorphisms [3]. Several other published
literatures also supported that the rare CNVs in NRXN1
g e n em a yb ea s s o c i a t e dw i t h schizophrenia and other
mental disorders. However, schizophrenia has been
regarded as a complex disease, so there might be many
susceptibility genes associated with this disease. To
explain the association of polymorphisms with complex
disorders, we have two models, the ‘common disease/
common variant’ (CDCV) and ‘common disease/rare
variant’ (CDRV) model [23]. The CDCV model of schi-
zophrenia suggests that relative common (often > 5%)
genetic variants in population might confer minor or
modest risk (i.e., OR = 1.1-1.5). On the other hand, the
CDRV model postulates that complex traits might
derive from many rare mutations for individuals (usually
<1%) but with relative strong effects (i.e., perhaps OR >
10). In the present study, we want to discuss that com-
mon SNPs in NRXN1 gene, other than rare CNVs,
might also be associated with schizophrenia in Chinese
Han population. We focused on the association of six
Figure 1 Linkage disequilibrium plot consist of 6 SNPs at the
NRXN1 gene and its regional plots. Pairwise linkage
disequilibrium (LD) was computed for all possible combinations of
the six SNPs using D’ values. Six SNPs were plotted with the -log10
(P-values) in the NRXN1 genomic position (in the University of
California Santa Cruz March 2006 human reference sequence, hg18).
Estimated recombination rates of SNPs in NRXN1 regions (taken
from HapMap Japanese in Tokyo (JPT) + Chinese Han in Beijing
(CHB)) are plotted to reflect the local LD structure. The index
association SNP is represented by a diamond. Color of the
remaining SNPs (circles) indicates LD with the index SNP based on
pairwise r
2 values from HapMap data.
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near the NRXN1 5’UTR with schizophrenia. And our
data of both SNPs and haplotypes showed that the
NRXN1 might be a susceptibility gene of schizophrenia
in Chinese Han population.
Walsh et al. reported that novel deletions and duplica-
tions of NRXN1 gene presented more frequently cases
(15%) and young-onset cases (20%) with schizophrenia
than those in controls (5%) [4]. In the present study, we
did not do any association analyses of child-onset schi-
zophreia with NRXN1 polymorphisms, since we have
only five patients with age-at-onset less than 12 years
old in our 768 patients with schizophrenia. Although we
did association tests between early-onset (<18 years old)
schizophrenia and NRXN1 polymorphisms, we did not
find an association. In all, we did not find any associa-
tion of NRXN1 polymorphisms with age-at-onset of
schizophrenia. This may be partly explained by the eth-
n i cd i f f e r e n c ea c r o s sv a r i o u spopulations. The diversity
of genotype and allele distributions between two popula-
tions might be responsible for the discrepancy. Another
possibility is that different genetic markers (SNPs and
CNVs) might be linked with different disease status or
clinical characteristics. Furthermore, the definition of
age-at-onset of schizophrenia may also vary across stu-
dies. These diversities of clinical assessment also in
some extent elucidated for the inconsistent findings
across studies. Other clinical examinations or endophe-
notypes of schizophrenia need to be evaluated when
further genetic association studies are implemented. The
relationship between the genetic variants in the middle
or 3’-end region of NRXN1 gene and schizophrenia
would be verified in the future study.
Conclusions
Our case-control association study suggested that
NRXN1 gene may play a role in genetic susceptibility to
schizophrenia. On the other hand, the different ethnic
genetic structure of NRXN1 gene might influence the
association of the polymorphisms with age-at-onset.
Furthermore, our results also reinforce the need for the
detailed LD mapping, CNV analysis of NRXN1 in differ-
ent population or other neurodevelopmental disorders.
The biological effect of risk variants and haplotypes in
the NRXN1 gene associated with schizophrenia, and
their role in disease pathogenesis and clinical character-
istics, needs to be explored.
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